Novartis has announced that delpacibart braxlosiran (del-brax), an investigational therapy for facioscapulohumeral muscular dystrophy (FSHD), has met the primary endpoint in the biomarker cohort of the Phase 1/2 FORTITUDE clinical trial.
What does this mean?
Del-brax is designed to target DUX4, the gene widely considered to drive the disease process in FSHD. In this study, treatment led to a significant reduction in KHDC1L, a biomarker linked to DUX4 activity, as well as a reduction in creatine kinase (CK), a marker associated with muscle damage.
These findings suggest that the therapy is successfully engaging its intended target and influencing the underlying biology of FSHD.
What happens next?
The Phase 1/2 FORTITUDE study was designed to evaluate safety, dosing and biological activity. These results represent an important milestone and support the continued development of del-brax.
The global Phase 3 FORTITUDE-3 trial is already underway. Phase 3 studies involve larger numbers of participants and are designed to determine whether a treatment leads to meaningful improvements in strength, function and daily life for people living with FSHD. ![]()
![]()
![]()
What does this mean for the FSHD community?
These findings provide further evidence that targeting DUX4 may be a viable therapeutic approach for FSHD and bring us one step closer to the possibility of disease-modifying treatments.
While these results are encouraging, it is important to remain cautiously optimistic. We still need to see the full clinical data and understand whether the biological effects observed translate into meaningful benefits for people living with FSHD.
FSHD Europe welcomes this progress and thanks everyone who contributed by participation in the clinical trials, their families and support networks, and the scientists, clinicians and researchers working to advance FSHD research.
Would you like to find out more?
Read the full Novartis press release: https://www.novartis.com/…/novartis-delpacibart….
Learn more about FSHD research and how to participate in studies and trials: https://fshd-europe.info/research/#participate